Yuting MA
Yuting MA
Chinese Academy of Medical Sciences, Université Paris Descartes, INSERM
Bestätigte E-Mail-Adresse bei crc.jussieu.fr
Zitiert von
Zitiert von
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors
F Ghiringhelli, L Apetoh, A Tesniere, L Aymeric, Y Ma, C Ortiz, ...
Nature medicine 15 (10), 1170-1178, 2009
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice
M Michaud, I Martins, AQ Sukkurwala, S Adjemian, Y Ma, P Pellegatti, ...
Science 334 (6062), 1573-1577, 2011
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
A Sistigu, T Yamazaki, E Vacchelli, K Chaba, DP Enot, J Adam, I Vitale, ...
Nature medicine 20 (11), 1301-1309, 2014
Consensus guidelines for the detection of immunogenic cell death
O Kepp, L Senovilla, I Vitale, E Vacchelli, S Adjemian, P Agostinis, ...
Oncoimmunology 3 (9), e955691, 2014
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells
Y Ma, S Adjemian, SR Mattarollo, T Yamazaki, L Aymeric, H Yang, ...
Immunity 38 (4), 729-741, 2013
Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy
Y Ma, L Aymeric, C Locher, SR Mattarollo, NF Delahaye, P Pereira, ...
Journal of Experimental Medicine 208 (3), 491-503, 2011
Autophagy and cellular immune responses
Y Ma, L Galluzzi, L Zitvogel, G Kroemer
Immunity 39 (2), 211-227, 2013
A dual role for autophagy in a murine model of lung cancer
S Rao, L Tortola, T Perlot, G Wirnsberger, M Novatchkova, R Nitsch, ...
Nature communications 5 (1), 1-15, 2014
Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors
SR Mattarollo, S Loi, H Duret, Y Ma, L Zitvogel, MJ Smyth
Cancer research 71 (14), 4809-4820, 2011
Molecular mechanisms of ATP secretion during immunogenic cell death
I Martins, Y Wang, M Michaud, Y Ma, AQ Sukkurwala, S Shen, O Kepp, ...
Cell Death & Differentiation 21 (1), 79-91, 2014
Cardiac glycosides exert anticancer effects by inducing immunogenic cell death
L Menger, E Vacchelli, S Adjemian, I Martins, Y Ma, S Shen, T Yamazaki, ...
Science translational medicine 4 (143), 143ra99-143ra99, 2012
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
L Zitvogel, Y Ma, D Raoult, G Kroemer, TF Gajewski
Science 359 (6382), 1366-1370, 2018
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
E Vacchelli, Y Ma, EE Baracco, A Sistigu, DP Enot, F Pietrocola, H Yang, ...
Science 350 (6263), 972-978, 2015
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer
L Senovilla, E Vacchelli, J Galon, S Adjemian, A Eggermont, WH Fridman, ...
Oncoimmunology 1 (8), 1323-1343, 2012
Chemotherapy and radiotherapy: cryptic anticancer vaccines
Y Ma, O Kepp, F Ghiringhelli, L Apetoh, L Aymeric, C Locher, A Tesniere, ...
Seminars in immunology 22 (3), 113-124, 2010
Harnessing γδ T cells in anticancer immunotherapy
D Hannani, Y Ma, T Yamazaki, J Déchanet-Merville, G Kroemer, ...
Trends in immunology 33 (5), 199-206, 2012
Binary cooperative prodrug nanoparticles improve immunotherapy by synergistically modulating immune tumor microenvironment
B Feng, F Zhou, B Hou, D Wang, T Wang, Y Fu, Y Ma, H Yu, Y Li
Advanced Materials 30 (38), 1803001, 2018
Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands
R Conforti, Y Ma, Y Morel, C Paturel, M Terme, S Viaud, B Ryffel, ...
Cancer research 70 (2), 490-500, 2010
Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy
H Yang, Y Ma, G Chen, H Zhou, T Yamazaki, C Klein, F Pietrocola, ...
Oncoimmunology 5 (6), e1149673, 2016
Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects
O Kepp, L Menger, E Vacchelli, S Adjemian, I Martins, Y Ma, ...
Oncoimmunology 1 (9), 1640-1642, 2012
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20